The post‑hoc analyses of the REDEFINE 1 phase 3 trial, presented at ObesityWeek and published in Hypertension on November 6, 2025, show that CagriSema lowered mean systolic blood pressure by 10.9 mmHg over 68 weeks, a 2.1 mmHg improvement over semaglutide 2.4 mg and 8.8 mmHg over placebo. The same data set reports a 68.9 % reduction in high‑sensitivity C‑reactive protein, compared with 55.4 % for semaglutide and 16.0 % for placebo, indicating a marked anti‑inflammatory effect.
In addition to cardiovascular markers, the trial’s primary endpoint—weight loss—reached a mean reduction of 22.7 % in patients who adhered to the treatment regimen and 20.4 % under a treatment‑policy analysis. These figures are comparable to the 23 % weight loss observed with Eli Lilly’s tirzepatide in the SURMOUNT‑1 study, underscoring CagriSema’s potential to compete on both weight‑loss efficacy and cardiovascular benefit.
Patients receiving CagriSema reported gastrointestinal side effects that were mild to moderate and consistent with the profile of GLP‑1 receptor agonists. The side‑effect burden did not appear to limit adherence, as evidenced by the robust weight‑loss outcomes.
Novo Nordisk’s executive vice president for development, Martin Holst Lange, highlighted the significance of the findings: “These analyses confirm that combining cagrilintide with semaglutide delivers meaningful reductions in blood pressure and systemic inflammation, while maintaining a strong weight‑loss signal.” The company plans to leverage the data to support accelerated regulatory submissions for expanded indications, including cardiovascular disease and metabolic dysfunction‑associated steatohepatitis, and to inform the design of the ongoing REDEFINE 3 cardiovascular outcomes trial.
The results reinforce Novo Nordisk’s competitive moat against rivals such as Eli Lilly’s tirzepatide. By offering a dual‑action therapy that addresses obesity, hypertension, and inflammation, CagriSema could capture a larger share of the growing obesity‑cardiovascular market, complement its flagship products Wegovy and Ozempic, and provide a new revenue stream that aligns with the company’s long‑term growth strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.